Could Pan-Immune-Inflammation Value Be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?
Overview
Toxicology
Affiliations
Inflammation plays a key role in the pathogenesis of the coronary slow flow phenomenon (CSFP). The newly developed inflammatory marker, pan-immune-inflammation value (PIV), is associated with adverse cardiovascular events. This study investigated the predictive value of PIV for diagnosing CSFP in comparison to other inflammation-based markers. A total of 214 patients, 109 in the CSFP group and 105 in the normal coronary flow (NCF) group, were retrospectively included in the study. Coronary flow was calculated using the Thrombolysis in Myocardial Infarction frame count method. In addition to PIV, other inflammatory markers such as neutrophil-lymphocyte ratio, platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated for the patients. The average age of patients was 50.3 ± 8.4, with a male ratio of 55.1%. Compared to the NCF group, patients in the CSFP group had higher levels of hyperlipidemia, glucose, triglyceride, NLR, PLR, SII, and PIV, while their high-density lipoprotein cholesterol (HDL-C), was lower (p < 0.05). Logistic regression analysis demonstrated that HDL-C, glucose, triglyceride, and PIV were independent predictor factors for CSFP (p < 0.05). PIV is a strong and independent predictor factor for CSFP and superior in predicting CSFP compared to other inflammatory markers.
Guo J, Xiang Z, Ma D Int J Gen Med. 2025; 18:1325-1332.
PMID: 40070680 PMC: 11895676. DOI: 10.2147/IJGM.S516108.
Yilu Z, Zhanglong W, Fanke H, Jing G, Yue W, Yuwen C Medicine (Baltimore). 2025; 103(52):e41094.
PMID: 39969298 PMC: 11688051. DOI: 10.1097/MD.0000000000041094.
Serhatlioglu F, Cetinkaya Z, Yilmaz Y J Cardiovasc Dev Dis. 2024; 11(11).
PMID: 39590180 PMC: 11594304. DOI: 10.3390/jcdd11110337.
Wen Z, Long J, Wang Y BMC Cardiovasc Disord. 2024; 24(1):595.
PMID: 39462315 PMC: 11515272. DOI: 10.1186/s12872-024-04281-4.
Karaduman A, Yilmaz C, Keten M, Balaban I, Kultursay B, Danisman N Biomark Med. 2024; 18(21-22):957-967.
PMID: 39431313 PMC: 11633389. DOI: 10.1080/17520363.2024.2412515.